Myotonic dystrophy type 2 (DM2) is an autosomal dominant muscular dystrophy caused by the expansion of an intronic tetranucleotide CCTG repeat in CNBP on chromosome 3. As DM1, DM2 is a multisystem disorder affecting, beside the skeletal muscle, various other tissues, including peripheral nerves. Indeed, a subclinical involvement of peripheral nervous system has been described in several cohorts of DM2 patients, whereas DM2 patients manifesting clinical signs and/or symptoms of neuropathy have been only rarely reported. Here, we describe 2 related DM2 patients both of whom displayed an atypical disease onset characterized by dysautonomic symptoms, possibly secondary to peripheral neuropathy.

Keywords:
Myotonic dystrophy type 2, Peripheral neuropathy, Dysautonomia, Fluorescent in situ hybridization, Nerve biopsy
1.
Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP: Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864–867.
2.
Udd B, Krahe R: The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11: 891–905.
3.
Hilbert JE, Ashizawa T, Day JW, Luebbe EA, Martens WB, McDermott MP, Tawil R, Thornton CA, Moxley RT: Diagnostic odyssey of patients with myotonic dystrophy. J Neurol 2013; 260: 2497–2504.
4.
Hermans MC, Faber CG, Vanhoutte EK, Bakkers M, De Baets MH, de Die-Smulders CE, Merkies IS: Peripheral neuropathy in myotonic dystrophy type 1. J Peripher Nerv Syst 2011; 16: 24–29.
5.
Peric S, Stojanovic VR, Nikolic A, Kacar A, Basta I, Pavlovic S, Lavrnic D: Peripheral neuropathy in patients with myotonic -dystrophy type 1. Neurol Res 2013; 35: 331–335.
6.
Nojszewska M, Łusakowska A, Szmidt-Salkowska E, Gaweł M, Lipowska M, Sułek A, Krysa W, Rajkiewicz M, Seroka A, Kaczmarek K, Kamińska AM: Peripheral nerve involvement in myotonic dystrophy type 2 – similar or different than in myotonic dystrophy type 1? Neurol Neurochir Pol 2015; 49: 164–170.
7.
Leonardis L: Peripheral neuropathy in patients with myotonic dystrophy type 2. Acta Neurol Scand 2017; 135: 568–575.
8.
Kimura J: Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. 3rd (ed). Oxford, Oxford University Press, 2001.
9.
Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G: Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 2004; 48: 437–442.
10.
Santoro M, Masciullo M, Pietrobono R, Conte G, Modoni A, Bianchi ML, Rizzo V, Pomponi MG, Tasca G, Neri G, Silvestri G: Molecular, clinical, and muscle studies in myotonic dystrophy type 1 (DM1) associated with novel variant CCG expansions. J Neurol 2013; 260: 1245–1257.
11.
Young NP, Daube JR, Sorenson EJ, Milone M: Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 2010; 41: 758–762.
12.
Pelargonio G, Dello Russo A, Sanna T, De Martino G, Bellocci F: Myotonic dystrophy and the heart. Heart 2002; 88: 665–670.
13.
Wahbi K, Meune C, Bécane HM, Laforêt P, Bassez G, Lazarus A, Radvanyi-Hoffman H, Eymard B, Duboc D: Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 2009; 19: 468–472.
14.
Flachenecker P, Schneider C, Cursiefen S, Ricker K, Toyka KV, Reiners K: Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM). Neuromuscul Disord 2003; 13: 289–293.
15.
Magrì D, Piccirillo G, Bucci E, Pignatelli G, Cauti FM, Morino S, Latino P, Santini D, Marrara F, Volpe M, Antonini G, Testa M: Increased temporal dispersion of myocardial repolarization in myotonic dystrophy type 1: beyond the cardiac conduction system. Int J Cardiol 2012; 156: 259–264.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.